Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Collagen peptide blood study completed in three healthy women

NCT ID NCT07195396

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study involved 3 healthy women aged 35-45 who took hydrolyzed collagen peptides. Blood samples were taken 1 and 2 hours later to measure collagen-derived peptides and amino acids. The goal was to collect serum for future lab experiments on skin cells, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3 people

The number who actually took part.

Started

Oct 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is able and willing to sign the Informed Consent Form prior to screening evaluations * Age: 35 - 45 years * Women * BMI: 19 - 25 kg/m2 * Non-smoker * Participant is in good physical and mental health as established by medical history, physical examination, electrocardiogram, vital signs, results of biochemistry and haematology at screening Exclusion Criteria: * Relevant history or presence of any severe medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro-intestinal diseases, heavy depression, diabetes, significant CVD events, acute cancers within last 3 years except basal cell carcinoma of the skin, etc.) * Significant changes in lifestyle or medication (within last 3 mo.) or surgical intervention or surgical procedure such as bariatric surgery * Application of corticoids (intravenously, orally or intraarticularly) and other immune-suppressing drug (within last 2 weeks) * Blood donation within 1 month prior to study start or during study * Low haemoglobin levels \< 12 g/dL * Regular intake of drugs or supplements possibly interfering with this study within 2 weeks prior to study start or during study (stable medication since \> 3 months e.g. L-Thyroxin, blood pressure medication etc. allowed) * Chronic intake of substances affecting blood coagulation (e.g. acetylic acid, anticoagulants (e.g. Marcumar), diuretics, thiazides), which in the investigator's opinion would impact participant safety * Not willing to avoid intake of pain relievers e.g. Paracetamol or Ibuprofen 24h prior to study days * Participants with history of drug, alcohol or other substance abuse, or other factors limiting their ability to co-operate during the study * History of hypersensitivity to fish * HIV-infection, acute or chronic hepatitis B and C infection * Known pregnancy, breast feeding or intention to become pregnant during the study. A pregnancy test will be conducted during screening and visits 1-5. * Participation in another clinical study within the last 4 weeks and concurrent participation in another clinical study * Anticipating any planned changes in lifestyle for the duration of the study * Participants considered inappropriate for the study by investigators, including participants who are unable or unwilling to show compliance with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy women are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • BioTeSys GmbH

    Esslingen am Neckar, 73728, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.